Last reviewed · How we verify
Daratumumab full dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Daratumumab full dose (Daratumumab full dose) — Assistance Publique - Hôpitaux de Paris.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Daratumumab full dose TARGET | Daratumumab full dose | Assistance Publique - Hôpitaux de Paris | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Daratumumab full dose CI watch — RSS
- Daratumumab full dose CI watch — Atom
- Daratumumab full dose CI watch — JSON
- Daratumumab full dose alone — RSS
Cite this brief
Drug Landscape (2026). Daratumumab full dose — Competitive Intelligence Brief. https://druglandscape.com/ci/daratumumab-full-dose. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing